Exploring OCT Changes After Repeated Red-Light Therapy for Myopia Prevention

As myopia continues to escalate globally, the potential of red-light therapy to reshape eye health is being explored with cautious optimism through meticulous OCT analysis.

Low-level red-light therapy (LLRLT, ~650 nm wavelength) has been associated with short-term changes in axial length and choroidal thickness in children with myopia. Some clinical trials report reduced axial elongation and transient choroidal thickening; however, long-term efficacy and guideline adoption remain under evaluation.

OCT often shows short-term choroidal thickening after sessions; evidence for retinal vascular changes is limited and inconsistent. OCT-based observations of short-term structural responsiveness have been described in peer-reviewed reportssource. These findings highlight tissue responsiveness observable on OCT and may inform evolving treatment strategies, pending longer-term safety and efficacy data.

In research settings and select clinics, OCT metrics are being used to monitor responses and adjust myopia control strategies, including investigational red-light protocols. These structural shifts are primarily biometric; direct, sustained improvements in visual acuity have not been consistently demonstrated. While some anecdotes mention clearer vision, current evidence centers on biometric changes rather than immediate, consistent subjective vision gains.

Randomized trials provide encouraging signals but vary in quality and duration, with ongoing evaluation of safety and rebound effects.

By influencing ocular biometrics, the therapy may help slow myopic progression in some patients, though responses vary and depend on adherence and dosing. Factors such as age, baseline risk, and treatment parameters likely modulate effect sizes and durability.

Clinicians should critically appraise emerging evidence and consider participation in controlled implementation or trials to clarify benefits and risks.

Key Takeaways:

• LLRLT is associated with slowed axial elongation and transient choroidal thickening on OCT; long-term efficacy and safety remain under study.
• Use of OCT to monitor LLRLT responses is mostly confined to research and select clinics; broad guideline endorsement has not occurred.
• Clinical focus should remain on biometric progression metrics; consistent visual acuity gains have not been demonstrated.
• Participation in trials and cautious, protocol-driven implementation can help clarify dosing, adherence effects, and rebound risks.